Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
2068 patients around the world
Available in Brazil
This is a prospective, randomized, double-blind, double-dummy and placebo-controlled
study in individuals with disabling migraine. The participants will be randomized to
receive Rizatriptan + Naproxen (10/550mg), Rizatriptan (10mg), Naproxen (550mg) or
placebo.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail
if your center is outside brazil).
